| Non‐platinum single‐agent versus platinum‐based combination treatment |
| Author, Year |
Intervention |
ITT population |
Median age (range) |
Elderly |
| Vansteenkiste 2001 |
G arm: gemcitabine 1000 mg/m2 D1, D8, D15 q28 days |
84 |
63.7 (55.5–71.9) |
NA |
|
CV arm: cisplatin 100 mg/m2 + vindesine 3 mg/m2 D1, D15 q 28 days |
85 |
63.1 (54.5–71.7) |
NA |
| Le Chevalier 1994 |
N arm: vinorelbine 30 mg/m2 weekly |
206 |
60 (NA) |
NA |
|
PN arm: cisplatin 120 mg/m2 D1, D29, then every 6 weeks + vinorelbine 30 mg/m2 weekly |
206 |
59 (NA) |
NA |
|
PV arm: cisplatin 120 mg/m2 D1, D29, then every 6 weeks + vindesine 3 mg/m2 weekly for 6 weeks, then every 2 weeks |
200 |
59 (NA) |
NA |
| Depierre 1994 |
PV arm: cisplatin 80 mg/m2 on D1 every 3 weeks and vinorelbine 30 mg/m2 weekly |
121 |
59.2 (NA) |
NA |
| |
V arm: vinorelbine 30 mg/m2 weekly |
119 |
58.8 (NA) |
NA |
|
Manegold 1998 (Europe) |
G arm: gemcitabine 1000 mg/m2 D1, D8, D15 q28 days |
71 |
59 (32‐80) |
NA |
|
EP arm: cisplatin 100 mg/m2 D1 + etoposide 100 mg/m2 D1, D2, D3 q28 days |
75 |
59 (33–78) |
NA |
|
Manegold 1998 (Taiwan) |
G arm: gemcitabine 1250 mg/m2 D1, D8, D15 q28 days |
27 |
63 (36–75) |
NA |
|
EP arm: cisplatin 100 mg/m2 D1 + etoposide 100 mg/m2 D1, D2, D3 q28 days |
26 |
60 (35–75) |
NA |
| Perng 1997 |
G arm: gemcitabine 1250 mg/m2 D1, D8, D15 q28 days |
27 |
63 (36–75) |
NA |
|
EP arm: cisplatin 80 mg/m2 D1 + etoposide 80 mg/m2 D1, D2, D3 q28 days |
26 |
63 (35‐75) |
NA |
| Jeremic 1997 |
E arm: etoposide 50 mg/m2/d D1 to D21 every 28 days |
59 |
NA |
NA |
|
EP arm: carboplatin 400 mg/m2 D1 + etoposide 50 mg/m2 D1 to D21 every 28 days |
58 |
NA |
NA |
| Rosso 1988 |
E arm: etoposide 120 mg/m2 D1, D2, D3 q21 days |
113 |
NA |
NA |
|
EP arm: cisplatin 60 mg/m2 D1, D2 + etoposide 120 mg/m2 D1, D2, D3 |
103 |
NA |
NA |
| Total |
|
1366 |
|
NA |
| Non‐platinum combination versus platinum combination |
| Author, Year |
Intervention |
ITT population |
Median age (range) |
Elderly |
| Berghmans 2013 |
GIP arm: gemcitabine 1000 mg/m2 on days 1 and 8 + ifosfamide 3000 mg/m2 on day 1 + cisplatin 50 mg/m2 on day 1 |
231 |
58 (29‐78) |
NA |
| |
DP arm: docetaxel 75 mg/m2 + cisplatin 50 mg/m2 on day 1 |
233 |
58 (28‐81) |
NA |
| |
IG arm: ifosfamide 3000 mg/m2 + gemcitabine 1000 mg/m2 on days 1 and 8 |
229 |
59 (30‐84) |
NA |
| Saito 2012 |
CP arm: carboplatin AUC6 plus paclitaxel 200 mg/m2 on day 1, every 3 weeks |
41 |
65 (20‐77) |
NA |
| |
GV arm: gemcitabine 1000 mg/m2 plus vinorelbine 25 mg/m2 on days 1 and 8, every 3 weeks |
43 |
67 (34‐76) |
NA |
| Hsu 2008 |
GE arm: gemcitabine 1000 mg/m2 on days 1, 8, 15 plus epirubicin 70 mg/m2
|
43 |
62.3 (33.9–78.6) |
NA |
| |
GP arm: gemcitabine 1000 mg/m2 on days 1, 8, 15 plus cisplatin on day 15 |
42 |
60.9 (37.6–76) |
NA |
| Gricorescu 2007 |
GV/GI arm: gemcitabine 1000 mg/m2 plus vinorelbine 25 mg/m2 on days 1 and 8 for 2 cycles, followed by gemcitabine 1000 mg/m2 on days 1 and 8 plus ifosfamide 2000 mg/m2 on day 1 for 2 cycles |
50 |
59 (NA) |
NA |
| |
GP arm: gemcitabine 1250 mg/m2 on days 1 and 8 plus cisplatin 70 mg/m2 on day 1 for 4 cycles |
52 |
56 (NA) |
NA |
| Yamamoto 2006 |
GV arm: gemcitabine 1000 mg/m2 plus vinorelbine 25 mg/m2 on days 1 and 8 |
64 |
62 (36‐74) |
NA |
| |
GC arm: gemcitabine 1000 mg/m2 on days 1 and 8 plus carboplatin AUC5 on day 1 |
64 |
60 (30‐74) |
NA |
| Katakami 2006 |
DG arm: docetaxel 60 mg/m2 on day 1 plus gemcitabine 800 mg/m2 on days 1 and 8, every 3 weeks |
65 |
NA |
NA |
| |
CD arm: cisplatin 80 mg/m2 plus docetaxel 60 mg/m2 on day 1, every 3 weeks. |
68 |
NA |
NA |
| Mok 2005 |
GE arm: gemcitabine 1000 mg/m2 on days 1, 8, and 15 plus etoposide 50 mg/m2 p.o. from day 1 through day 14, every 4 weeks |
45 |
61 (38‐70) |
NA |
| |
GP arm: cisplatin 75 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1, 8, and 15, every 4 weeks |
44 |
56 (23‐72) |
NA |
| Tan 2005 |
GV arm: gemcitabine 1000 mg/m2 plus vinorelbine 25 mg/m2 on days 1 and 8, every 3 weeks |
157 |
57 (29–74) |
NA |
| |
CV arm: carboplatin AUC5 on day 1 plus vinorelbine 30 mg/m2 on days 1 and 8, every 3 weeks |
159 |
60 (30–75) |
NA |
| Pujol 2005 |
GD arm: gemcitabine 1000 mg/m2 days 1 and 8 plus docetaxel 85 mg/m2 day 8, every 3 weeks |
155 |
60 (37–75) |
NA |
| |
CV arm: cisplatin 100 mg/m2 on day 1 plus vinorelbine 30 mg/m2 on days 1, 8, 15, and 28, every 4 weeks for 6 cycles |
156 |
57 (39–75) |
NA |
| Lilenbaum 2005b |
GV arm: vinorelbine 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8, every 3 weeks |
82 |
66 (42–86) |
NA |
| |
CP arm: paclitaxel 200 mg/m2 plus carboplatin AUC6 on day 1, every 3 weeks |
83 |
63 (38–86) |
NA |
| Stathopoulos 2004 |
PV arm: paclitaxel 135 mg/m2 plus vinorelbine 25 mg/m2 on day 1, every 2 weeks |
175 |
65 (36‐84) |
NA |
| |
CP arm: carboplatin AUC6 and paclitaxel 175 mg/m2 on day 1, every 3 weeks |
185 |
65 (30‐83) |
NA |
| Yamamoto 2004 |
DI arm: docetaxel 60 mg/m2 on day 8 and irinotecan 60 mg/m2 on days 1 and 8, every 3 weeks |
57 |
60 (42‐77) |
NA |
| |
CD arm: cisplatin 80 mg/m2 and docetaxel 60 mg/m2 on day 1, every 3 weeks |
51 |
62 (39‐74) |
NA |
| Alberola 2003 |
GV‐VI arm: gemcitabine 1000 mg/m2 and vinorelbine 30 mg/m2 on days 1 and 8, every 3 weeks for 3 cycles, followed by vinorelbine 30 mg/m2 on days 1 and 8 plus ifosfamide 3 g/m2 on day 1 for 3 cycles |
187 |
60 (33‐76) |
NA |
| |
GC arm: cisplatin 100 mg/m2 on day 1 plus gemcitabine 1250 mg/m2 on days 1 and 8, every 3 weeks |
182 |
59 (39‐74) |
NA |
| |
CGV arm: cisplatin 100 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 plus vinorelbine 25 mg/m2 on days 1 and 8, every 3 weeks |
188 |
59 (33‐75) |
NA |
| Smit 2003 |
GPac arm: paclitaxel 175 mg/m2 on day 1 plus gemcitabine 1250 mg/m2 on days 1 and 8, every 3 weeks |
161 |
56 (31‐75) |
NA |
| |
CG arm: cisplatin 80 mg/m2 on day 1 plus gemcitabine 1250 mg/m2 on days 1 and 8, every 3 weeks |
160 |
57 (28‐75) |
NA |
| |
CP arm: cisplatin 80 mg/m2 plus paclitaxel 175 mg/m2 on day 1, every 3 weeks |
159 |
57 (27‐75) |
NA |
| Wachters 2003 |
GE arm: epirubicin 70 mg/m2 on day 1 plus gemcitabine 1125 mg/m2 on days 1 and 8, every 3 weeks |
121 |
60 (32‐76) |
NA |
| |
CG arm: cisplatin 80 mg/m2 on day 2 plus gemcitabine 1125 mg/m2 on days 1 and 8, every 3 weeks |
119 |
60 (29‐80) |
NA |
| Sculier 2002 |
IG arm: ifosfamide 4500 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1, 8, and 15, every 4 weeks |
94 |
52 > 60 years old |
NA |
| |
CCI arm: cisplatin 60 mg/m2 and carboplatin AUC3 and ifosfamide 4500 mg/m2 over 18‐hour i.v. infusion on day 1, every 4 weeks |
94 |
45 > 60 years old |
NA |
| |
CCG arm: cisplatin 60 mg/m2 on day 1 plus carboplatin AUC3 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8, and 15, every 4 weeks |
92 |
52 > 60 years old |
NA |
| Chen 2002 |
PG arm: paclitaxel 175 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1 and 8, every 3 weeks |
45 |
67 (35‐80) |
NA |
| |
CP arm: carboplatin AUC7 on day 1 plus paclitaxel 175 mg/m2 on day 1, every 3 weeks |
45 |
64 (37‐77) |
NA |
| Buccheri 1997 |
MACC arm: methotrexate 40 mg/m2, doxorubicin 40 mg/m2 i.v., cyclophosphamide 400 mg/m2 i.v. infusion, and lomustine 30 mg/m2 per os on day 1, every 3 weeks |
78 |
64 (NA) |
NA |
| |
MVP arm: mitomycin C 10 mg/m2, vinblastine 6 mg/m2, and cisplatin 40 mg/m2 i.v. infusions on day 1, every 3 weeks |
78 |
65 (NA) |
NA |
| Hara 1990 |
MCT arm: mitomycin C 4 mg/body i.v. infusion and cytosine arabinoside 30 mg/body on days 1, 4, 14, 21, and 28 and tegafur 600 mg orally every day |
67 |
63 (37‐75) |
NA |
| |
CAPM arm: cyclophosphamide 400 mg/m2 i.v. infusion on day 1, Adriamycin 30 mg/m2 i.v. infusion on day 1, cisplatin 60 mg/m2 i.v. infusion on day 1, and mitomycin C 3 mg/m2 i.v. infusion on day 1 |
69 |
60 (27‐75) |
NA |
| Total |
|
5040 |
|
|
